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Abstract
Background: Methadone maintenance treatment (MMT) is a key element in treatment for opiate addiction;
however concerns about the diversion of methadone remain. More current empirical data on methadone diversion
are required. This research investigated the market for diverted methadone in Merseyside, UK, in order to provide a
case study which can be transferred to other areas undertaking methadone maintenance treatment on a large
scale.
Methods: Questionnaires were completed (in interview format) with 886 past year users of methadone recruited
both in and out of prescribing agencies. Topic areas covered included current prescribing, obtaining and providing
methadone, reasons for using illicit methadone and other drug use.
Results: Large proportions of participants had obtained illicit methadone for use in the past year with smaller
proportions doing so in the past month. Proportions of participants buying and being given methadone were
similar. Exchange of methadone primarily took place between friends and associates, with ‘dealers’ rarely involved.
Gender, age, whether participant’s methadone consumption was supervised and whether the aims of their
treatment had been explained to them fully, influenced the extent to which participants were involved in diverting
or using diverted methadone.
Conclusion: Methadone diversion is widespread although drug users generally do not make use of illicit
methadone regularly (every month). The degree of altruism involved in the exchange of methadone does not
negate the potential role of this action in overdose or the possibility of criminal justice action against individuals.
Treatment agencies need to emphasise these risks whilst ensuring that treatment aims are effectively shared with
clients to ensure adherence to treatment.
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Background
Evidence of Methadone Diversion
Whilst the effectiveness of the various models of metha-
done treatment has been established through interna-
tional research [1-5], concerns have been expressed
about the potential ‘leakage’ of methadone onto the
‘black market’ and the increased risk of harm that this
entails [6-8]. The diversion of methadone has been
implicated as a key contributing factor in fatal and non-
fatal methadone poisonings [9-12]. The risk of street
selling of methadone and its association with overdose
have also been recognised by drug users being pre-
scribed substitute medication [13].
Investigative studies in developed countries have
examined the prevalence and nature of methadone
diversion and illicit use [14-17]. Findings suggest metha-
done is used and sold illicitly at a high level relative to
other prescription opioids, although the diversion of
buprenorphine has also become widespread [18]. Illicit
methadone use is associated with recent heroin use
[14,19,20] and methadone is used illicitly in conjunction
with other illegal substances, such as illicit benzodiaze-
pines [21]. It is usually administered orally however stu-
dies conducted with drug users in England and
Australia reveal injecting of oral solution [22-24].
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illicit market for prescription methadone is generated.
Illicit methadone is commonly used as self-medication
for the management of withdrawal symptoms by opiate
addicted individuals not engaged in treatment [20,25]. It
is also obtained by clients in treatment looking to sup-
plement their own methadone prescription or replace
their prescription after failing to obtain it due to missed
appointments or prescription pick-ups [21,25,26]. A key
motive for selling prescribed methadone is to raise
funds to buy other, preferred, drugs or to pay for private
prescriptions which cannot be obtained as part of the
free provision of care [27]. Common tactics used to
obtain excess methadone for illicit sale include acquiring
more than one prescription and obtaining a higher
dosage than required [28]. The cost of methadone on
the illicit market fluctuates according to supply and
demand [27].
Protocols for Prescribing and Dispensing Methadone
Prescribing and dispensing practices can facilitate or
hinder the diversion of methadone; overly large dosages
and ‘take-home’ prescriptions have been strongly asso-
ciated with accelerated diversion [8,29]. Official guide-
lines for the prescribing and dispensing of methadone in
the UK state that measures should be taken to prevent
diversion, mainly implementing supervised consumption
and prescribing methadone in its oral form [30,31].
However variations in prescribing protocols are apparent
between UK regions and individual prescribers [32-34]
and prescribing often deviates from guidelines [35]. Pre-
scribing and dispensing practices also vary internation-
ally, in terms of the doses of methadone prescribed
[36,37] and the use of supervised consumption [38].
Historically, concerns about diversion have been a trig-
ger for increased regulation [35].
Methadone Diversion in Merseyside
Merseyside (population 1,353,400 in 2010 [39]) is a
mixed rural and urban, affluent and deprived, county in
the North West of England and it has been identified as
a diverse area with relatively high problematic drug use
in some parts and not in others [40]. The diversity of
the area and its population make it good candidate for a
study of this type and findings will be transferable to
other areas undertaking methadone maintenance on a
large scale. During the 1980s Merseyside saw a ‘heroin
epidemic’ [41]. An inter-agency approach to tackling
this major heroin problem using methadone mainte-
nance therapy (MMT) alongside other harm reduction
approaches successfully reduced the prevalence of illicit
drug use and acquisitive crime, although methadone
leakage became a concern [42]. Although models of
drug treatment in the UK are becoming more ‘recovery’
focused, with greater focus on rehabilitation, recovery
networks and reintegration [43], MMT remains a key
element in the treatment for opiate addiction both
nationally and in the region [44]. During the year 2009/
10, 8,759 drug users accessed general practitioner or
specialist prescribing in Merseyside (C. Gibbons, perso-
nal communication, February 23, 2011). However
methadone diversion remains an issue, with drug users
coming into contact with drugs workers in custody
suites reporting illicit methadone use via national moni-
toring systems.
Research Aims
Further empirical data on the magnitude and trends of
the diversion of prescription opioids are needed to
inform clinical decisions and risk management [38,45].
Little recent published work has investigated the diver-
sion of methadone in England. This research aimed to
examine the extent and nature of methadone diversion
from the perspective of a large sample of opiate users in
Merseyside. Findings will inform drug treatment practi-
tioners and commissioners across the UK as to the
mechanics of the market for illicit methadone, to enable
them to consider best practice in addressing the issue of
diversion with clients. There are difficulties transferring
learning on this topic to other countries due to large
variations in treatment delivery approach, drugs used
and legislation but it is hoped that many aspects of the
findings will be of use to practitioners and commis-
sioners involved in the delivery of MMT in other coun-
tries with established treatment systems.
Methodology
Participants
Participants were recruited from 28 sites across Mersey-
side between November 2008 and September 2010. Sites
included primary prescribing services (community drugs
teams), agencies providing treatment specifically for
offenders, service user forums and services providing
accommodation for drug users. Recruitment approaches
varied from site to site but generally advertising materi-
als were placed in waiting rooms/communal areas or
handed out by practitioners indicating when members
of the research team would be in attendance. On the
designated recruitment days the research team attended
the service and approached individuals within commu-
nal areas or practitioners directed potential participants
to them. Any individual over 18 and who had used
methadone (licit or illicit) in the previous year was
eligible.
Materials
A 28 item questionnaire with a mixture of closed and
open questions was developed after an examination of
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drug treatment practitioners. Topics covered included
current prescribing, obtaining and providing methadone,
reasons for using illicit methadone and other drug use.
No personal details aside from age and gender were col-
lected to ensure confidentiality and reassure participants
in an attempt to promote full disclosure. Before com-
mencing the interview all participants were asked to
confirm that they had not taken part in the interview
previously.
Procedure
Once participants had indicated their desire to take part
in the study they received a full explanation of the pro-
ject (verbal and written) including assurances around
confidentiality and were asked to provide written con-
sent for their participation. The questionnaire was com-
pleted by the researcher in an interview with the
participants (lasting approximately 15 minutes). Partici-
pants received a travel voucher (worth £4) as reimburse-
ment for their time.
Analysis
All analysis was conducted using PASW Statistics 17.0.
The Chi-square test for association was used for com-
parisons across categorical items (e.g. gender) and inde-
pendent measures t-tests were applied for continuous
data (e.g. age of participants).
Ethics
The design and procedure of the project, including the
questionnaires, were reviewed and approved by both the
authors’ university ethics committee and a National
Health Service Research Ethics Committee.
Results
Sample Characteristics
A total of 886 participants were recruited aged between
18 and 64 years old (mean 38, sd 7.03). The majority of
the sample were male (71%). These characteristics are
broadly similar to national (England) figures for indivi-
duals engaged in treatment in 2009/10 (median age 33,
73% male) [46]. In 2009/10 the total number of indivi-
duals receiving General Practitioner or agency based
prescribing in Merseyside was 7,392. The sample repre-
sents 12% of this population or 7% of the estimated opi-
ate using population within the geography (latest
available estimate for 2008/9) [47]. The majority of par-
ticipants (86%) were prescribed methadone at the time
of their interview, with all but 29 of the sample pre-
scribed methadone within the past year. Among those
participants currently prescribed methadone, 85% were
receiving doses of 80 mg a day or less (28% of the sam-
ple were receiving less than 40 mg a day). Frequent
prescription pick-ups were the norm with 72% of parti-
cipants picking up daily and 22% several times a week.
Reasons for using prescribed methadone
Participants reported a wide variety of reasons for
obtaining a prescription, primarily ‘to avoid withdrawal’
(84% of participants), ‘to aid them to achieve abstinence’
(22%), ‘to relieve unpleasant mental states e.g. anxiety’
(18%), ‘to stabilise their lifestyle’ (11%) or ‘to stop them
committing crime’ (8%). Regardless of the reasons sta-
ted, high levels of satisfaction were reported with pre-
scribed methadone’s ability to achieve this goal with
only 5% of participants claiming that methadone was
ineffective for their stated expectation.
Supervision
More than half of the sample (53%), were not on super-
vised consumption at the point they were interviewed,
so many were in a position to divert their methadone if
that was their desire. Among those supervised, 60% said
they would prefer not to be and gave a variety of rea-
sons for this including embarrassment at taking metha-
done in the chemist, inconvenience and a desire for
greater control over the time and location of use includ-
ing splitting doses (half in the morning and half in the
evening). A lack of satisfaction with supervision was sig-
nificantly associated with clients feeling that the reasons
why they were on supervision had not been explained to
them fully (c2 = 13.23, p < 0.05).
Size of the market
60% of participants suggested that at some point in the
past year they had obtained illicit methadone whilst 22%
said they had done so in the past four weeks. This iden-
tifies the presence of a substantial market for diverted
methadone. However, the discrepancy between current
(4 wks) and previous (yr) usage, suggests that it is not a
market that clients routinely use. Much lower propor-
tions of clients reported providing methadone to others
over the same time periods (14% past year, 5% past 4
wks). It may be that clients were less willing to discuss
the provision of their methadone to others for fear that
it would prejudice their future treatment despite reas-
surances to the contrary. Analysis supported this as
there was a significant association between where clients
were recruited and reports of providing methadone in
the previous year (c2 = 34.924, p < 0.001). A greater
proportion of participants recruited outside of their pre-
scribing agency reported providing their methadone to
others than those recruited at the agency (28% com-
pared to 11%).
The size of the market is also indicated by reports
from clients about the number of people they knew
who regularly provided or obtained methadone
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who provided their methadone to others at least once
am o n t hw h i l s t7 2 %k n e wa t least one person who
obtained illicit methadone at least once a month. For
both obtaining and providing methadone more than
three in ten participants said they knew more than five
people who engaged in this activity at least once a
month (Figure 1).
Questions about price revealed that 100 mg of metha-
done rarely cost more than £10 (only 3% of participants
reported paying over this amount in the past year).
The nature of the market
Most diversion of methadone was reported to take place
between friends or associates. Very small proportions of
participants undertook transactions with an individual
they identified as a ‘dealer’ although where money was
exchanged (to either buy or sell methadone) dealers
were more commonly reported (however still in a small
proportion of cases). When obtaining methadone the
market would appear to be split equally into a cash
based process (43% of participants had bought metha-
done in the past year) and a process where methadone,
on the surface, is provided for free (44% of participants
had been given methadone in the past year). Money was
less likely to be involved when participants were provid-
ing their methadone to others with 13% of participants
giving away their methadone in the past year compared
to 5% who reported selling it. Participant’s reticence to
admit monetary gain from the process may in part
explain the lower proportions of individuals reporting
selling methadone (Table 1).
Clients who obtained methadone in the past year were
significantly older than their counterparts who had not
obtained methadone (t(884) = -2.436, p < 0.05). How-
ever there was no significant difference in the ages of
c l i e n t sw h oh a do rh a dn o tp r o v i d e dm e t h a d o n et o
others (t(884) = 0.121, ns). The gender of participants
was significantly associated with the provision of metha-
done in the past year (c2 = 4.982, p < 0.05) but not
with obtaining methadone (c2=0 . 0 1 6 ,n s ) .O n ei nt e n
female participants (10%) reported providing methadone
to others in the past year compared to 16% of males.
Participant’s perceptions of the effectiveness of their
prescribed methadone and their current prescribed dose
levels were not significantly associated with obtaining or
providing methadone either in the past year or past 4
weeks. Whether participants were currently supervised
was significantly associated with obtaining (c2 = 10.699,
p < 0.005) and providing methadone (c2 = 6.479, p <
0.05) in the past year (supervised participants more
likely to have obtained methadone but less likely to have
provided methadone) and providing methadone in the
past four weeks (c2 = 7.341, p < 0.01) (supervised parti-
cipants less likely to report providing methadone in the
past four weeks) but there was no association between
supervision and obtaining methadone in the past 4
weeks (c2 = 0.322, ns). Obtaining methadone in the
past year (c2 = 7.111, p < 0.01) and past 4 weeks (c2=
4.481, p < 0.05) were also significantly associated with
participant’s perceptions about the extent to which the
aims of their treatment had been explained to them. In
both cases clients who felt that the aims of their treat-
ment had not been fully explained to them were more
Figure 1 Number of individuals participants knew who regularly provided or obtained methadone illegally.
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Diversion Activity Time period Number (%) Who from/to Number (%)
Been given methadone (n = 885) Past Yr 387 (44) Friend/Associate 346 (89)
Partner 30 (8)
Relative 9 (2)
Doctor 2 (1)
Dealer 10 (3)
Other 8 (2)
Past 4 wks 126 (14) Friend/Associate 112 (88)
Partner 10 (10)
Relative 4 (4)
Doctor 4 (3)
Dealer 0
Other 2 (2)
Bought Methadone (n = 884) Past Yr 382 (43) Friend/Associate 343 (90)
Partner 3 (1)
Relative 0
Doctor
Dealer 19 (5)
Other 14 (4)
Past 4 wks 131 (15) Friend/Associate 119 (91)
Partner 0
Relative 0
Doctor 0
Dealer 6(5)
Other 3 (2)
Given away methadone (n = 854) Past Yr 111 (13) Friend/Associate 84 (76)
Partner 30(27)
Relative 4(4)
Doctor 0
Dealer 0
Other 0
Past 4 wks 35 (4) Friend/Associate 24 (69)
Partner 11(31)
Relative 1(3)
Doctor 0
Dealer 0
Other 0
Traded methadone (n = 855) Past Yr 28 (3) Friend/Associate 27(96)
Partner 0
Relative 0
Doctor 0
Dealer 1(4)
Other 1(4)
Past 4 wks 9 (1) Friend/Associate 9(100)
Partner 0
Relative 0
Doctor 0
Dealer 0
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citly (Table 2).
Discussion
Rates of methadone diversion or use of diverted metha-
done seen in this study indicate the presence of a rela-
tively large active ‘black market’ for methadone which a
substantial proportion of participants had utilised but in
general not regularly, evidenced by the differences
between proportions of clients reporting obtaining illicit
methadone in the past year compared to past four
weeks. This suggests that there are specific circum-
stances under which this occurs. Due to different popu-
lations, national policies and time frames, comparisons
of rates of use identified in this study with those from
other countries are difficult. Among opiate users in New
York studies have shown high rates of lifetime illicit
methadone use (53% [48] and 72% [14]), and relatively
high recent use (21.3% in the previous 6 months) [48].
Among a population of heroin users in Montreal, 42%
had used illicit methadone in the previous 6 months
[19]. In Dublin, 73% of opiate users presenting for treat-
ment had used illicit methadone and 55% used at least
once whilst in treatment [25]. In Australia among a
sample presenting for drug treatment, 51% had used
methadone illicitly in the year before presentation [24].
Comparisons with other geographies can also prove dif-
ficult due to the differing levels of ‘treatment penetra-
tion’. Areas where access to treatment is relatively easy
with short waiting times would be assumed to have less
need for drug users to turn to the use of street drugs or
to diverted methadone thereby minimising the market.
Table 2 Interaction of individual factors with diversion activity
Factor Obtained methadone
in past year
Obtained methadone
in past 4 weeks
Provided Methadone
in past year
Provided methadone in
past 4 weeks
Number Number Number Number
Gender Male (n = 631) 379 132 98 37
Female (n = 255) 152 66 25* 4
Is methadone
effective
Yes (n = 725) 410 149 88 37
No (n = 40) 25 11 7 4
Dose Level High (above 80 mg/
day) (n = 113)
71 31 19 9
Low (below 80 mg/
day) (n = 650)
363 129 75 32
Currently Supervised Yes (n = 362) 228 79 33 11
No (n = 402) 206*** 81 61* 30**
Aims of treatment
fully explained
Yes (n = 652) 358 128 76 34
No (n = 111) 76** 32* 18 7
*Significant at p < 0.05, **Significant at p < 0.01, ***Significant at p < 0.005
Table 1 Numbers of participants reporting diversion activity and who with (Continued)
Other 1(11)
Sold methadone (n = 854) Past Yr 46 (5) Friend/Associate 43(93)
Partner 1(2)
Relative 0
Doctor 0
Dealer 0
Other 3(7)
Past 4 wks 14 (2) Friend/Associate 14(100)
Partner 0
Relative 0
Doctor 0
Dealer 0
Other 0
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to prescribing with short waiting times therefore it
could be assumed this is not a major driver for the size
of the diverted methadone market.
The reportedly low price of illicit methadone in Mer-
seyside (as seen in other research [24]) suggests that
there is a large enough supply in the market to keep
this price low [49-51].
A large proportion of clients reported being prescribed
under the optimal dose levels recommended in the UK
guidelines on clinical management of drug use and
dependence [30] which are suggested to be 60-120 mg a
day. A phenomenon of under prescribing is not unique
to the UK having been reported in a number of other
countries [52,53]. There is a considerable body of evi-
dence that higher doses are associated with more posi-
tive treatment outcomes [36,54-59] and doses over 100
mg of methadone have been associated with more posi-
tive outcomes in terms of tests for illicit opiates [60]. So
the ‘topping up’ that has been seen in this study and in
others [26] may be associated with the relatively low
levels of prescribing reported by participants. However,
high levels of satisfaction with the effectiveness of
methadone in achieving participant’s stated reasons for
using methadone and a lack of association between per-
ceptions of effectiveness or dose levels and diversion
suggest that it is not a lack of efficacy of prescribed
methadone that is a driver for the illicit market. This
supports findings from other work [26] which indicated
that adequacy of dose was not related to levels of illicit
methadone use. The impact of prescribing higher doses
of methadone in terms of clients’ potential desire (and
the desire of the current UK Government) to move
t o w a r d sa b s t i n e n c ea ss o o na sp o s s i b l ea l s or e q u i r e s
some consideration. Higher doses may lead to greater
dependency on methadone and subsequent longer, more
difficult periods of detoxification.
High proportions of clients on supervised consump-
tion reporting dissatisfaction with this status raises some
potential issues with disengagement from services, espe-
cially if reasons for not liking supervision are as emotive
as embarrassment due to the locality of chemists or the
lack of appropriate private consumption rooms [61]
which are critical in clients satisfaction with supervised
consumption [62]. Also within the framework of the
current UK focus on recovery [43] with clients being
reintegrated into mainstream society as quickly as is
safe, factors such as inconvenience and a lack of control
over prescribing have potential to disempower drug
users seeking to make positive changes [63-65]. How-
ever, this must be balanced against the health risks
posed by unregulated use of methadone in the commu-
nity both to individuals already prescribed, those not
engaging with services and non drug users [66-68].
Previous work has suggested that taking the opposite
approach, starting unsupervised and moving to super-
vised when concerns around appropriate use become
apparent, can lead to greater attrition [69]. Disempower-
ment and disengagement are also potential outcomes if
clients feel that they are not a part of their treatment
planning [44,70] and, in this study, participants who felt
that they had not had the aims of their treatment
explained were more likely to report ‘topping up’ their
methadone prescription. In addition levels of satisfaction
with being on supervised consumption were associated
with the degree to which participants felt the reasons
for this had been explained to them fully.
The desire for additional control over when and how
methadone could be taken e.g. some in the morning
and some in the afternoon, may be linked to partici-
pants anxiety about the ability of their methadone to
hold them for the full 24 hrs [71] despite the fact that
as long as dosing is correct the pharmacology of metha-
done should mean this presents no problem. This may
link again though to the relatively low doses being pre-
scribed, although as outlined most participants found
that their methadone was effective for their purposes.
Supervised consumption was associated with lower
levels of past year and past four week diversion implying
that having this control in place is effective, despite
doubts expressed by drug treatment agency key workers
in Merseyside [27]. Findings support previous work indi-
cating that supervised consumption can promote adher-
ence to prescribed methadone use [72]. The high
frequency of pick-ups reported should also mean that
individuals do not have large quantities to pass on at
any one time, unless they are stockpiling, and should
help to guarantee adherence to treatment [72].
The methadone market does not appear to be com-
mercially motivated with most diversion happening
between friends or associates (not with ‘dealers’)a n d
often with no money changing hands, suggesting a con-
siderable altruistic element or the expectation of reci-
procation in the future. It may also be indicative of a
process of self medication among drugs users. Clients
who are self titrating (only by small amounts at a time)
will have small amounts of methadone left over which
are then available to friends and associates. Despite this
non commercial profile legal considerations remain.
Individuals caught with someone else’s prescription or
caught passing their prescription to another person
could face substantial criminal sanctions (methadone is
controlled under Class A of the Misuse of Drugs Act
1971 with a potential sentence of up to life in prison for
an offence of supply or seven years for possession). In
reality the risk of detection may be relatively small and
it is not clear that in all cases criminal justice agencies
would apply the full measure of the law. In addition this
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intent on doing so and who are likely to have an exist-
ing criminal record. Despite this it may be prudent for
practitioners to emphasise this potential consequence of
diversion along with clinical aspects e.g. overdose [9-12].
It is not clear why older participants should be more
likely to report obtaining illicit methadone in the past
year. It may be that these individuals are more likely to
have received methadone treatment previously, in the
past have had more reason to utilise the market for
methadone [26] and know other drug users who have
access to methadone when compared to younger clients
who may not have been prescribed in the past. From
the data collected for this study it is not clear why
females should be less likely to provide methadone to
others than males. It may reflect a number of factors
including; greater risks perceived by this group in terms
of the impact on dependants if they were caught provid-
ing methadone (and an associated fear of revealing
diversion); a higher perceived need for treatment among
this group (previous studies have suggested females are
more likely to use street methadone possibly indicating
an increased need for treatment [20] or greater levels of
motivation for recovery. Unfortunately this is not an
area that has been investigated in previous work on
methadone diversion. It is a point that will need to be
tackled in future research.
Study Limitations
The possibility of underreporting particularly among
participants recruited within prescribing agencies must
be considered (as seen from findings where individuals
recruited outside prescribing agencies reported higher
levels of diversion and use of the diverted methadone).
In particular clients who are diverting their methadone
on a large scale are unlikely to agree to discuss this with
a researcher who is asking about methadone diversion.
Removal of this under reporting would only serve to
increase the suggested size of the market which is
already assessed as being considerable. The potential
reticence of participants to discuss diversion with an
independent researcher, who has no involvement with
the delivery of treatment raises questions about the
extent to which clients would report any diversion to
clinicians. As practitioners have reported that objective
measures to detect diversion (e.g. drug testing) are not
effective [61] subjective judgements must be relied upon
which are not reliable and if action is based on these it
is likely to cause conflict.
Measures to ensure that individuals felt comfortable
discussing a sensitive topic such as collecting the bare
minimum of personal details may introduce the possibi-
lity that participants were interviewed twice. A small
group of interviewers and the use of a filter question to
determine prior completion should have minimised this
issue.
This sample in this study was mostly of a group that
have been engaged with treatment relatively recently,
further investigation with opiate users not in contact
with treatment is required to better understand the
experiences of this group as potential consumers of
diverted methadone. However, as a general rule a num-
ber of those clients engaged in treatment must at some
point be the suppliers of methadone so their perception
of individuals involved in the market can be considered
accurate.
Conclusions
Whilst there continues to be a considerable market for
diverted methadone, opiate users would generally appear
to make use of it relatively infrequently. Supervision
would appear to be an appropriate measure for control-
ling diversion, however the potential effect of its long
term imposition on a client’s recovery journey should be
considered especially as long term restrictions on take
home doses have been shown to impede treatment
engagement [73,74]. The market is characterised as
much altruism as by commercial motivation but the
health and criminal justice risks posed by diversion to
individuals attempting to tackle their addiction remain
considerable. Treatment agencies need to emphasise
these risks whilst ensuring that treatment aims are effec-
tively shared with clients to ensure adherence to
treatment.
Acknowledgements
The authors would like to thank those who contributed to this paper, by
providing valuable input into the research design and materials (in particular
Debbie Holt and David Young), the fieldwork team and the agencies who
supported recruitment.
Author details
1Criminal Justice System Manager, Centre for Public Health, Liverpool John
Moores University, 2
nd Floor, Henry Cotton Campus, 15-21 Webster Street,
Liverpool, L3 2ET, UK.
2Researcher in Substance Misuse, Centre for Public
Health, Liverpool John Moores University, 2
nd Floor, Henry Cotton Campus,
15-21 Webster Street, Liverpool, L3 2ET, UK.
Authors’ contributions
PD conceived of the study, participated in its design, conducted the analysis
and produced the final manuscript. HB led on the design and co-ordination
of the study (including fieldwork), conducted and wrote the literature
review. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 September 2011 Accepted: 13 January 2012
Published: 13 January 2012
References
1. Van Ameijden E, Langendam E, Coutinho R: Dose-effect relationship
between overdose mortality and prescribed methadone dosage in low-
threshold maintenance programs. Addict Behav 1999, 24:559-563.
Duffy and Baldwin Harm Reduction Journal 2012, 9:3
http://www.harmreductionjournal.com/content/9/1/3
Page 8 of 102. Risser D, Honigschnabl S, Stichenwirth M, Pfudl S, Sebald D, Kaff A, Bauer G:
Mortality of opiate users in Vienna, Austria. Drug Alc Depend 2001,
64:251-256.
3. King VL, Stoller KB, Hayes M, Umbricht A, Currens M, Kidorf MS, Carter JA,
Schwartz R, Brooner RK: A multicenter randomized evaluation of
methadone medical Maintenance. Drug Alc Depen 2002, 65:137-148.
4. Farre M, Mas A, Torrens M, Moreno V, Cami J: Retention rate and illicit
opioid use during methadone maintenance interventions: a meta-
analysis. Drug Alc Depen 2002, 65:283-290.
5. Gossop M, Stewart D, Browne N, Marsden J: Methadone treatment for
opiate dependent patients in general practice and specialist clinic
settings: outcomes at 2-year follow-up. Journal of Substance Abuse
Treatment 2003, 24:313-321.
6. Neale J: Methadone, methadone treatment and non-fatal overdose. Drug
Alc Depend 2000, 58:117-124.
7. Weinrich M, Stuart M: Provision of methadone treatment in primary care
medical practices: review of the Scottish experience and implications for
US policy. JAMA 2000, 283:1343-8.
8. Heinemann A, Iwersen-Bergmann S, Stein S, Schmoldt A, Püschel K:
Methadone-related fatalities in Hamburg 1990-1999: implications for
quality standards in maintenance treatment? Forensic Sci Int 2000,
113:449-455.
9. Seymour A, Black M, Jay J, Cooper G, Weir C, Oliver J: The role of
methadone in drug-related deaths in the west of Scotland. Addiction
2003, 98:995-1002.
10. Corkery J, Schifano F, Ghodse H, Oyefeso A: The effects of methadone and
its role in fatalities. Hum Psychopharm Clin 2004, 19:565-576.
11. Graham NA, Merlo LJ, Goldberger BA, Gold MS: Methadone- and heroin-
related deaths in Florida. Am J Drug Alcohol Ab 2008, 34:347-53.
12. Madden ME, Shapiro SL: The Methadone Epidemic: Methadone-Related
Deaths on the Rise in Vermont. Am J Foren Med and Path 2011,
32:131-135.
13. Neale J: Drug users’ views of substitute prescribing conditions. Int J of
Drug Policy 1999, 10:247-258.
14. Davis W, Johnson B: Prescription opioid use, misuse, and diversion
among street drug users in New York City. Drug and Alcohol Dependence
2008, 92:267-276.
15. Mitchell SG, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, Ruhfa A,
Agar MH, O’Grady KE, Schwartz RP: Uses of diverted methadone and
buprenorphine by opioid addicted individuals in Baltimore, Maryland.
The Am J Addiction 2009, 18:346-355.
16. Dasgupta N, Bailey EJ, Cicero T, Inciardi J, Parrino M, Rodenblum A, Dart RC:
Post-marketing surveillance of methadone and buprenorphine in the
United States. Pain Medicine 2010, 11:1078-1091.
17. Hoare J, Moon D: Drug misuse declared: findings from the 2009/10
British Crime Survey: England and Wales. London: Home Office; 2010.
18. Winstock AR, Lea T, Sheridan J: Prevalence of diversion and injection of
methadone and buprenorphine among clients receiving opioid
treatment at community pharmacies in New South Wales, Australia. Int J
Drug Policy 2008, 19:450-458.
19. Lauzon P, Vincelette J, Bruneau J, Lamothe F, Lachance N, Brabant M,
Soto J: Illicit use of methadone among IV drug users in Montreal. J Subst
Abuse Treat 1994, 11:457-461.
20. Vlahov D, O’Driscoll P, Mehta SH, Ompad DC, Gern R, Galai N, Kirk GD: Risk
factors for methadone outside treatment programs: implications for HIV
treatment among injection drug users. Addiction 2007, 102:771-777.
21. Fountain J, Griffiths P, Farrell M, Gossop M, Strang J: Benzodiazepines in
polydrug-using repertoires: the impact of the decreased availability of
temazepam gel-filled capsules. Drug- Educ Prev Polic 1999, 6:61-69.
22. Sunjic S, Howard J: “Non injectables": methadone syrup and
benzodiazepine injection by methadone-maintained clients. Drug Alc Rev
1996, 15:245-250.
23. Gossop M, Marsden J, Stewart D, Treacy S: Routes of drug administration
and multiple drug misuse: regional variations among clients seeking
treatment at programmes throughout England. Addiction 2000,
95:1197-1206.
24. Winstock AR, Lea T: Diversion and injection of methadone and
buprenorphine among clients in public opioid treatment clinics in New
South Wales, Australia. Subst Use Misuse 2010, 45:240-52.
25. Roche A, McCabe S, Smyth BP: Illicit methadone use and abuse in young
people accessing treatment for opiate dependence. Eur Addict Res 2008,
14:219-25.
26. Best D, Harris J, Gossop M, Farrell M, Finch E, Noble A, Strang J: Use of
non-prescribed methadone and other illicit drugs during methadone
maintenance treatment. Drug Alcohol Rev 2000, 19:9-16.
27. Fountain J, Strang J, Gossop M, Farrel M, Griffiths P: Diversion of
prescribed drugs by drug users in treatment: analysis of the UK market
and new data from London. Addiction 2000, 95:393-406.
28. Fountain J, Griffiths P, Farrell M, Gossop M, Strang J: Diversion tactics: how
a sample of drug misusers in treatment obtained surplus drugs to sell
on the illicit market. Int J of Drug Policy 1997, 9:159-167.
29. Edmunds M, Hough M, Urquía N: Tackling local drug markets. London:
Home Office; 1996.
30. Department of Health (England) and the devolved administrations: Drug
misuse and dependence: UK guidelines on clinical management.
London: Department of Health (England), the Scottish Government, Welsh
Assembly Government and Northern Ireland Executive; 2007.
31. National Institute for Health and Clinical Excellence: Methadone and
buprenorphine for the management of opioid dependence. London,
NICE; 2007.
32. Matheson C, Bond C, Hickey F: Prescribing and dispensing for drug
misusers in primary care: current practice in Scotland. Fam Prac 1999,
16:375-379.
33. Strang J, Sheridan J: Methadone prescribing to opiate addicts by private
doctors: comparison with NHS practice in south east England. Addiction
2001, 96:567-576.
34. Strang J, Sheridan J, Hunt C, Kerr B, Gerada C, Pringle M: The prescribing of
methadone and other opioids to addicts: national survey of GPs in
England and Wales. Br J of Gen Prac 2005, 55:444-451.
35. Bell J: The global diversion of pharmaceutical drugs: opiate treatment
and the diversion of pharmaceutical opiates: a clinician’s perspective.
Addiction 2010, 105:1531-1537.
36. Mohamad N, Hidayah Abu Bakar N, Musa N, Talib N, Ismail R: Better
retention of Malaysian opiate dependents treated with high dose
methadone in methadone maintenance therapy. Harm Reduct J 2010,
7:30.
37. Chunqing L, Roger D: A qualitative study exploring the reason for low
dosage of methadone prescribed in the MMT clinics in China. Drug
Alcohol Depen .
38. Hall W, Degenhardt L: Regulating opioid prescribing to provide access to
effective treatment while minimizing diversion: an overdue topic for
research. Addiction 2007, 102:1685-1688.
39. Office for National Statistics: Mid year population estimates 2010: 30/06/
11. London: ONS; 2011.
40. Hay G, Gannon M, MacDougall J, Millar T, Eastwood C, McKeganey N:
Estimates of the prevalence of opiate use and/or crack cocaine use
(2006/07). London: Home Office; 2008.
41. Parker H, Newcombe R: Heroin Use and Acquisitive Crime in an English
Community. Br J Sociol 1987, 38:331-350.
42. Parker H, Kirby P: Methadone Maintenance and Crime Reduction on
Merseyside. London: Home Office Police Research Group; 1996.
43. Home Office: Drug strategy 2010: reducing demand, restricting supply,
building recovery: supporting people to live a drug free life. London:
Home Office; 2010.
44. Strang J: Recovery-orientated drug treatment: an interim report. London,
National Treatment Agency; 2011.
45. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ: Mechanisms of prescription
drug diversion among drug-involved club- and street-based
populations. Pain Med 2007, 8:171-183.
46. The National Treatment Agency for Substance Misuse: Statistics from the
National Drug Treatment Monitoring System (NDTMS) 1 April 2009 - 31
March 2010. London: The National Treatment Agency for Substance
Misuse; 2010.
47. Hay G, Gannon M, Casey J, Millar M: Estimates of the prevalence of opiate
use and/or crack cocaine use (2008/09) North West Region. London:
Home Office; 2009.
48. Colon HM, Robles RR, Deren S, Sahai H, Finlinson HA, Andia J, Cruz MA,
Kang SY, Oliver-Velez D: Between-city variation in frequency of injection
Duffy and Baldwin Harm Reduction Journal 2012, 9:3
http://www.harmreductionjournal.com/content/9/1/3
Page 9 of 10among Puerto Rican injection drug users: East Harlem, New York, and
Bayamon, Puerto Rico. J Acquir Immune Defic Syndr 2001, 27:405-413.
49. Caulkins JP, Reuter P, Iguchi MY, Chiesa J: How goes the war on drugs?
An assessment of US drug problems and policy. Santa Monica: RAND;
2005.
50. Wilson L, Stevens A: Understanding drug markets and how to influence
them. The Beckley Foundation Drug Policy Programme Report 14 London:
Beckley Foundation; 2007.
51. Schifano F, Corkery J: Cocaine/crack cocaine consumption, treatment
demand, seizures, related offences, prices, average purity levels and
deaths in the UK (1990–2004). J Psychopharmacol 2008, 22:71-79.
52. Pollack HA, D’Aunno T: Dosage Patterns in Methadone Treatment: Results
from a National Survey, 1988-2005. Health Serv Res 2008, 43:2143-2163.
53. Lin C, Detels R: A qualitative study exploring the reason for low dosage
of methadone prescribed in the MMT clinics in China. Drug Alc Depend
2011, 117:45-49.
54. McGlothlin WH, Anglin MD: Long-term follow-up of clients of high- and
low-dose methadone programs. Arch Gen Psychiatr 1981, 38:885-892.
55. Joe GW, Simpson DD, Hubbarb RL: Treatment predictors of tenure in
methadone maintenance. J Subst Abuse 1991, 3:73-84.
56. Caplehorn JRM, McNeil DR, Klienbaum DG: Clinic policy and retention in
methadone maintenance. Int J Addict 1993, 28:73-89.
57. Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Methadone dose and
treatment outcome. Drug Alc Depend 1993, 33:105-117.
58. Strain EC, Bigelow GE, Liebson IA, Stitzer ML: Moderate- vs High-Dose
Methadone in the Treatment of Opioid Dependence A Randomized
Trial. JAMA 1999, 281:1000-1005.
59. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P: Methadone
maintenance at different dosages for opioid dependence. Cochrane
Database of Systematic Reviews 2003, , 3: CD002208.
60. Fareed A, Casarella J, Roberts M, Sleboda M, Amar R, Vayalapalli S, Drexler K:
High Dose versus Moderate Dose Methadone Maintenance: Is There a
Better Outcome? J Addict Dis 2009, 28:399-405.
61. Baldwin HF, Duffy P: Stakeholders’ Perceptions of Methadone Diversion
and their Responses to it. Int J of Drug Policy .
62. Stone E, Fletcher R: User views on supervised methadone consumption.
Addict Bio 2003, 8:45-48.
63. Pani PP, Pirastu R, Ricci A, Gessa G L: Prohibition of take home dosages:
Negative consequences on methadone maintenance treatment. Drug Alc
Depend 1996, 41:81-84.
64. White JM, Ryan C F, Ali RL: Improvements in retention rates and changes
in client group with methadone maintenance streaming. Drug Alc Rev
1996, 15:83-88.
65. Ritter A, Di Natale R: The relationship between take-away methadone
policies and methadone diversion. Drug Alc Rev 2005, 24:347-352.
66. Beattie J: Children Poisoned with Illegal Drugs in Glasgow. BMJ 1999,
318:1137.
67. Li L, Levine B, Smialek JE: Fatal Methadone Poisoning in Children:
Maryland 1992-1996. Subst Use Misuse 2000, 35:1141-1148.
68. Strang J, Hall W, Hickman M, Bird SM: Impact of supervision of
methadone consumption on deaths related to methadone overdose
(1993-2008): analyses using OD4 index in England and Scotland. BMJ
2010, 341:4851.
69. Bell JR, Ryan A, Mutch C, Batey R, Rea F: Optimising the benefits of
unobserved dose administration for stable opioid maintenance patients:
Follow-up of a randomised trial. Drug Alcohol Depen 2008, 96:183-186.
70. Ernst DB, Pettinati HM, Weiss RD, Donovan DM, Longabaugh R: An
Intervention for Treating Alcohol Dependence: Relating Elements of
Medical Management to Patient Outcomes With Implications for Primary
Care. Ann Fam Med 2008, 6:435-440.
71. Tacke U, Wolff K, Finch E, Strang J: The effect of tobacco smoking on
subjective symptoms of inadequacy ("not holding”) of methadone does
among opiate addicts in methadone maintenance treatment. Addict Biol
2001, 6:137-145.
72. Haskew M, Wolff K, Dunn J, Bearn J: Patterns of adherence to oral
methadone: Implications for prescribers. J Subst Abuse Treat 2008,
35:109-115.
73. Deering DEA, Sheridan J, Sellman JD, Adamson SJ, Pooley S, Robertson R,
Henderson C: Consumer and treatment provider perspectives on
reducing barriers to opioid substitution treatment and improving
treatment attractiveness. Addict Behav 2011, 36:636-642.
74. Stone E, Fletcher K: User views on supervised methadone consumption.
Addict Biol 2003, 8:45-8.
doi:10.1186/1477-7517-9-3
Cite this article as: Duffy and Baldwin: The nature of methadone
diversion in England: a Merseyside case study. Harm Reduction Journal
2012 9:3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Duffy and Baldwin Harm Reduction Journal 2012, 9:3
http://www.harmreductionjournal.com/content/9/1/3
Page 10 of 10